Yelena Y. Janjigian
0000-0002-5357-5858
Publication & Citation Trends
Publications
715 total
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.
Cited by 1
Semantic Scholar
DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer
Cited by 0
Semantic Scholar
Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial
Cited by 2
Semantic Scholar
385TiP AZD0901 monotherapy in patients (pts) with advanced biliary tract cancer (BTC) expressing claudin18.2 (CLDN18.2): CLARITY-PanTumour01 substudy 3
Cited by 0
Semantic Scholar
270O Efficacy and safety of perioperative durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma in Asia: A subgroup analysis of the MATTERHORN trial
Cited by 0
Semantic Scholar
3072MO Datopotamab deruxtecan (Dato-DXd) + rilvegostomig (rilve) in patients (pts) with locally advanced or metastatic urothelial cancer (a/mUC): Results from the phase II TROPION-PanTumor03 study
Cited by 1
Semantic Scholar
313P Characteristics, treatment patterns, and outcomes with first-line nivolumab plus chemotherapy vs chemotherapy in CheckMate 649 patients by regions
Cited by 0
Semantic Scholar
LBA4 Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma
Cited by 4
Semantic Scholar
EDGE-Gastric Arm A1: Phase 2 study of domvanalimab (D), zimberelimab (Z), and FOLFOX in first-line (1L) advanced gastroesophageal (GE) cancer
Cited by 0
Semantic Scholar
297P First-line (1L) trastuzumab deruxtecan (T-DXd) 5.4 mg/kg + fluoropyrimidine (FP) + pembrolizumab (pembro) in advanced HER2+ gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma: updated results from DESTINY-Gastric03 (DG-03) Part 2F
Cited by 0
Semantic Scholar
Research Topics
Gastric Cancer Management and Outcomes
(468)
Esophageal Cancer Research and Treatment
(348)
Lung Cancer Treatments and Mutations
(213)
Cancer Immunotherapy and Biomarkers
(159)
Cancer Genomics and Diagnostics
(92)
Affiliations
U.S. National Science Foundation
Memorial Sloan Kettering Cancer Center
The University of Texas MD Anderson Cancer Center
Bayer (United States)
Merck (Germany)